Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial) (PACE-RBBB)

This study has been terminated.
(Lack of funding)
Sponsor:
Collaborator:
American Heart Association
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01169493
First received: July 22, 2010
Last updated: August 1, 2016
Last verified: August 2016
  Purpose
Heart failure (HF) affects 5 million Americans and is responsible for more health-care expenditure than any other medical diagnosis. Approximately half of all HF patients have electrocardiographic prolongation of the QRS interval and ventricular dyssynchrony, a perturbation of the normal pattern of ventricular contraction that reduces the efficiency of ventricular work. Ventricular dyssynchrony is directly responsible for worsening HF symptomatology in this subset of patients. Resynchronization of ventricular contraction is usually achieved through simultaneous pacing of the left and right ventricles using a biventricular (BiV) pacemaker or implantable cardioverter-defibrillator. Clinical trial evidence supporting the use of BiV pacing in patients with prolonged QRS duration was obtained almost exclusively in patients with a left bundle-branch block (LBBB) electrocardiographic pattern. Recent evidence suggests that resynchronization of ventricular contraction in patients with LBBB can be obtained by univentricular left ventricular pacing with equal or superior clinical benefits compared to BiV pacing. Animal studies suggest that ventricular resynchronization can be obtained in subjects with right bundle-branch block (RBBB) through univentricular right ventricular pacing. No clinical trial evidence exists to support the use of BiV pacing in patients with RBBB. Thousands of patients with symptomatic HF and RBBB currently have univentricular ICDs in place for the prevention of sudden cardiac death. Most of these devices are currently programmed to avoid RV pacing. We aim to determine if ventricular resynchronization delivered through univentricular RV pacing improves symptoms in patients with RBBB and moderate to severe HF who have previously undergone BiV ICD implantation for symptomatic heart failure. We further aim to determine if ventricular resynchronization improves myocardial performance and ventricular geometry as detected by echocardiographic measures and quality of life for patients with HF and RBBB. We hypothesize that RV univentricular pacing delivered with an atrio-ventricular interval that maximizes ventricular synchrony is equivalent to BiV pacing for improvement in cardiac performance, HF symptoms, and positive ventricular remodeling in patients with HF and RBBB.

Condition Intervention
Heart Failure
Right Bundle-Branch Block
Device: VVI-40
Device: RV DDD-40
Device: BiV DDD-40

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of >5mm. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary Echocardiographic Endpoints [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Comparisons of the derived velocity-time integral calculated on the aortic continuous wave Doppler-spectrogram, RV end-diastolic size, RV EF, mitral and tricuspid regurgitation severity, and estimated RV systolic pressure.

  • Arrhythmic Events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To determine if pacing mode impacts the frequency of ventricular arrhythmias, the incidence of ventricular tachyarrhythmia episodes on device interrogation will be compared between treatment group assignments. An episode will be considered ventricular arrhythmia if it lasts longer than 30 seconds or requires anti-tachycardia pacing or high voltage device therapy for termination.

  • Minnesota Quality of Life Questionnaire [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    This is a standardized method for assessing quality of life in patients with heart failure. It asks 21 questions and measures the impact HF has on a subject's life. Each question is rated 0-5. The total score for the 21 items can range from 0 to 105. Higher scores indicate more burden of disease on quality of life.

  • 6-minute Walk Distance [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    6-minute walk distance was the distance that a participant could walk in 6 minutes.

  • NYHA Function Class [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    The New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on how much they are limited during physical activity. Class I means there is no limitation of physical activity and Class IV means a person is unable to carry on any physical activity without discomfort/symptoms of heart failure at rest.

  • Left Ventricular Ejection Fraction (LVEF) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Left Ventricular End-diastolic Size [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: January 2011
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: VVI-40 to RV DDD-40 to Bi-V DDD-40
Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40
Experimental: VVI-40 to Bi-V DDD-40 to RV DDD-40
Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40
Experimental: Bi-V DDD-40 to VVI-40 to RV DDD-40
Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40
Experimental: Bi-V DDD-40 to RV DDD-40 to VVI-40
Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40
Experimental: RV DDD-40 to VVI-40 to Bi-V DDD-40
Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40
Experimental: RV DDD-40 to Bi-V DDD-40 to VVI-40
Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
Device: VVI-40
Pacing mode set to VVI-40, RV only pacing
Device: RV DDD-40
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
Device: BiV DDD-40
ICD programmed to BiV pacing at a lower rate of 40

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cardiomyopathy of either idiopathic or ischemic etiology
  • NYHA class III, or IV symptoms
  • Sinus rhythm
  • QRS complex duration > 130 msec in ≥ 2 surface ECG leads with RBBB
  • PR interval > 150 msec and < 240 msec
  • Prior implantation of dual chamber BiV ICD with apical RV lead location

Exclusion Criteria:

  • Myocardial infarction, major surgical procedure, or acute cardiac failure crisis requiring inotropes within 6 months of entry into the study
  • Atrial fibrillation or flutter lasting >12 hours within the last 6 months
  • Sick sinus syndrome, complete heart block, or other arrhythmias requiring pacemaker support
  • Pregnancy
  • Any other known condition other than heart failure that could limit exercise time or survival to < 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01169493

Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Durham VA Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
American Heart Association
Investigators
Principal Investigator: Brett D Atwater, MD Duke University
  More Information

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01169493     History of Changes
Other Study ID Numbers: Pro00025144  10CRP3630033 
Study First Received: July 22, 2010
Results First Received: August 28, 2015
Last Updated: August 1, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Heart Failure
Right Bundle-Branch Block
Cardiac Resynchronization Therapy

Additional relevant MeSH terms:
Heart Failure
Bundle-Branch Block
Heart Block
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes

ClinicalTrials.gov processed this record on September 27, 2016